MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY
Androgenic pathway plays a pivotal role in the development of benign and malignant prostate tumors. Most of the prostate neoplasms are hormone-dependent at the time of diagnosis. Therapeutic interventions aimed at reducing the level of testosterone in the blood allow to stop progression of the disea...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/286 |
| _version_ | 1826563818290937856 |
|---|---|
| author | G. S. Krasnov A. A. Dmitriev N. N. Volchenko T. V. Danilova A. F. Sadritdinova A. V. Snezhkina N. V. Melnikova M. S. Fedorova V. A. Lakunina A. A. Belova B. Y. Alekseev A. D. Kaprin A. V. Kudryavtseva |
| author_facet | G. S. Krasnov A. A. Dmitriev N. N. Volchenko T. V. Danilova A. F. Sadritdinova A. V. Snezhkina N. V. Melnikova M. S. Fedorova V. A. Lakunina A. A. Belova B. Y. Alekseev A. D. Kaprin A. V. Kudryavtseva |
| author_sort | G. S. Krasnov |
| collection | DOAJ |
| description | Androgenic pathway plays a pivotal role in the development of benign and malignant prostate tumors. Most of the prostate neoplasms are hormone-dependent at the time of diagnosis. Therapeutic interventions aimed at reducing the level of testosterone in the blood allow to stop progression of the disease. But over time, the tumor almost inevitably starts to progress, moving in the castration-resistant state (CRPC), representing a serious problem of oncourology. In recent years, the possibility of CRRPC therapy increased significantly – there was developed a number of new drugs that effectively inhibit the development of castration-resistant tumors and significantly push back the start of chemotherapy. This review describes the major drug targets and mechanisms of action of abiraterone, enzalutamide, galeterone, VT-464 and other approved and promising CRPC therapies. |
| first_indexed | 2024-04-10T01:54:35Z |
| format | Article |
| id | doaj.art-aed37ab4fd6d4f0bbd5f2ace0d68794b |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2025-03-14T10:10:00Z |
| publishDate | 2016-02-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-aed37ab4fd6d4f0bbd5f2ace0d68794b2025-03-02T11:16:06ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-01064553286MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPYG. S. Krasnov0A. A. Dmitriev1N. N. Volchenko2T. V. Danilova3A. F. Sadritdinova4A. V. Snezhkina5N. V. Melnikova6M. S. Fedorova7V. A. Lakunina8A. A. Belova9B. Y. Alekseev10A. D. Kaprin11A. V. Kudryavtseva12Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow P.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, Moscow V. N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, MoscowP.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, Moscow V. N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, MoscowV. N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, MoscowV. N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, MoscowP.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, MoscowP.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, MoscowEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow P.A. Herzen Moscow Cancer Research Institute, Ministry of Healthcare of the Russian Federation, MoscowAndrogenic pathway plays a pivotal role in the development of benign and malignant prostate tumors. Most of the prostate neoplasms are hormone-dependent at the time of diagnosis. Therapeutic interventions aimed at reducing the level of testosterone in the blood allow to stop progression of the disease. But over time, the tumor almost inevitably starts to progress, moving in the castration-resistant state (CRPC), representing a serious problem of oncourology. In recent years, the possibility of CRRPC therapy increased significantly – there was developed a number of new drugs that effectively inhibit the development of castration-resistant tumors and significantly push back the start of chemotherapy. This review describes the major drug targets and mechanisms of action of abiraterone, enzalutamide, galeterone, VT-464 and other approved and promising CRPC therapies.https://www.siboncoj.ru/jour/article/view/286castrate resistant prostate cancerandrogen receptorabirateroneenzalutamidemv3100galeteronevt-464cyp17а1 |
| spellingShingle | G. S. Krasnov A. A. Dmitriev N. N. Volchenko T. V. Danilova A. F. Sadritdinova A. V. Snezhkina N. V. Melnikova M. S. Fedorova V. A. Lakunina A. A. Belova B. Y. Alekseev A. D. Kaprin A. V. Kudryavtseva MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY Сибирский онкологический журнал castrate resistant prostate cancer androgen receptor abiraterone enzalutamide mv3100 galeterone vt-464 cyp17а1 |
| title | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY |
| title_full | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY |
| title_fullStr | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY |
| title_full_unstemmed | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY |
| title_short | MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY |
| title_sort | main molecular targets for prostate cancer therapy |
| topic | castrate resistant prostate cancer androgen receptor abiraterone enzalutamide mv3100 galeterone vt-464 cyp17а1 |
| url | https://www.siboncoj.ru/jour/article/view/286 |
| work_keys_str_mv | AT gskrasnov mainmoleculartargetsforprostatecancertherapy AT aadmitriev mainmoleculartargetsforprostatecancertherapy AT nnvolchenko mainmoleculartargetsforprostatecancertherapy AT tvdanilova mainmoleculartargetsforprostatecancertherapy AT afsadritdinova mainmoleculartargetsforprostatecancertherapy AT avsnezhkina mainmoleculartargetsforprostatecancertherapy AT nvmelnikova mainmoleculartargetsforprostatecancertherapy AT msfedorova mainmoleculartargetsforprostatecancertherapy AT valakunina mainmoleculartargetsforprostatecancertherapy AT aabelova mainmoleculartargetsforprostatecancertherapy AT byalekseev mainmoleculartargetsforprostatecancertherapy AT adkaprin mainmoleculartargetsforprostatecancertherapy AT avkudryavtseva mainmoleculartargetsforprostatecancertherapy |